Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|July 16, 2021

Tevogen Bio Partners with Yale in Regulatory Sciences Program Expansion

The Yale School of Public Health’s regulatory sciences program expansion builds on the current regulatory affairs track program, which focuses on the administrative, policy, and legal aspects of product regulation.

Tevogen Bio announced in a July 14, 2021 press release its support of the Yale School of Public Health’s regulatory sciences program expansion, providing students with professional training. This expanded program builds on the current regulatory affairs track in the Yale School of Public Health’s Master of Public Health program, which focuses on the administrative, policy, and legal aspects of product regulation.

Regulatory sciences on the other hand, focuses on the development of new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of products made by pharmaceutical, biologic, and medical device organizations, in addition to other industries.

“Stakeholders are searching for talented and emerging leaders in regulatory science, but current educational programs are scarce,” said Sten H. Vermund, Dean of the Yale School of Public Health, in a press release. “With Tevogen Bio’s support, we have an opportunity to reimagine our program and to grow it into one that matriculates students who ultimately become national and international leaders in the field.”

Source: BusinessWire, Tevogen


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.